We would like to introduce the data for a serological marker from our NASH model (STAM™ model).

Hepatocellular ballooning is a key finding distinguishing NASH from simple steatosis in terms of NASH diagnosis. CK-18 (cytokeratin 18) is known as one of the promising non-invasive biomarkers and was also recommended at the AASLD-FDA joint workshop because it is useful for diagnosing an early phase NASH.

 Elevates from 6 weeks of age, representing early NASH

- Gradually increases with progression of disease (from simple fatty liver to NASH, fibrosis)

- Shows similar rise to human NASH patients [Ariel E. Feldstein et al., Hepatology, 2009]